EZH2 and myelodysplastic syndrome: MiRNA-101, that is found to delay onset or progression to AML from MDS [108] and miRNA-124, which is a possible marker of response to DAC in MDS/AML [109], both repress cancer proliferation by EZH2 inhibition [110,111].